Category: Drugs and Pharmaceuticals

freeNewsArticles Story Summary: FORT LAUDERDALE, Fla. (SEND2PRESS NEWSWIRE) — Argentech, Inc. today announced that it reached agreement with Invision International Health Solutions, Inc., to purchase the rights to Opti-Silver, a patented antibacterial and antiviral technology that utilizes ionic silver in a unique complex for optimal delivery in the human body. The complex was granted broad…

freeNewsArticles Story Summary: SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies stuns the medical and scientific communities with a dramatic demonstration of single-agent efficacy with its lead product, Rexin-G, for metastatic cancer. The landmark article documents the results of two related studies using Rexin-G, a tumor-targeted anti-cancer agent designed to seek-out and destroy metastatic cancers…

freeNewsArticles Story Summary: SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies announced today that its lead product, Rexin-G, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for use as a second-line treatment for advanced or metastatic pancreatic cancer. The FDA Fast Track program, like Priority Review and Accelerated Approval,…

freeNewsArticles Story Summary: SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies’ Rexin-G is the world’s smallest hero. Imagine if you will, a tiny particle that can travel freely within the human body seeking out cancerous tissues and metastatic tumors that have spread far and wide. Imagine an entire army of these tiny nano-particles seeking out…

freeNewsArticles Story Summary: SAN MARINO, Calif., May 18 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies today announced the results of two related studies using Rexin-G®, a tumor-targeted anti-cancer agent designed to seek-out and destroy metastatic cancers that have spread throughout the body. While Rexin-G is currently approved for the treatment of all solid tumors in the Republic…

freeNewsArticles Story Summary: SAN MARINO, Calif., Feb. 12 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies announces the launch of its new informative website, containing an award-winning video and an interactive e-book designed to introduce the general public to the tumor-targeting and cancer-destroying biotechnologies behind the clinical development of Rexin-G. Honored as the first and so far only…

freeNewsArticles Story Summary: SAN MARINO, Calif., Jan. 19 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies announced the results of a U.S. Phase I/II study evaluating the safety and efficacy of Rexin-G in chemotherapy-resistant metastatic pancreatic cancer (ASCO GI Symposium, #249; Sant P Chawla, P.I., January 2009). Rexin-G was well tolerated and there was no dose-limiting toxicity. At…

freeNewsArticles Story Summary: FORT LAUDERDALE, Fla., Jan. 8 (SEND2PRESS NEWSWIRE) — The Silver Safety Committee today announced its creation of the Silver Safety Pyramid, which is designed to enable anyone to easily determine safe usage levels of any dietary supplement containing silver, typically referred to as ionic silver or colloidal silver.

freeNewsArticles Story Summary: SAN MARINO, Calif., Dec. 16 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation, a leader in tumor-targeted gene delivery systems, has received two additional European patents for the platform targeting technologies and molecular designs that enable precision gene delivery to primary cancers and metastatic lesions that have spread throughout the body. With profound demonstrations…

freeNewsArticles Story Summary: SAN MARINO, Calif., Nov. 20 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies announced today the results of Phase I/II and II studies of Rexin-G in chemotherapy-resistant metastatic soft tissue sarcoma and osteosarcoma, as presented by Dr. Sant P. Chawla, principal investigator, at the CTOS 14th annual meetings held in London UK on November 13-15,…